AstraZeneca PLC (AZN)
Nasdaq (ADR) / LSE · Cambridge, United Kingdom · Founded 1999 · CEO Pascal Soriot
Valuation summary
$155.48 fair value versus $175.41 in the market, a difference of -11.4%. Rated Hold.
| Fair value per share | $155.48 |
| Current share price | $175.41 |
| Upside / downside | -11.4% |
| Bear case | $95.82 |
| Bull case | $242.32 |
| Discount rate (WACC) | 8.8% |
| Terminal growth | 2.60% |
| Market capitalisation | $214B |
| EV / Sales | 3.8x |
About AstraZeneca PLC
Formed in 1999 from the merger of Sweden's Astra AB and Britain's Zeneca Group. Pascal Soriot has been CEO since 2012 and moved the headquarters and research base to Cambridge, England. AstraZeneca is strongest in oncology — Tagrisso, Imfinzi, Lynparza and the antibody-drug conjugate Enhertu, partnered with Daiichi Sankyo — plus biopharmaceuticals in cardiovascular, renal and metabolic disease including Farxiga, and respiratory and immunology. It has an unusually large China business for a Western pharmaceutical company.
Investment case
- One of the deepest oncology pipelines in the industry, with antibody-drug conjugates a genuine platform advantage.
- Rare disease through Alexion provides high-priced, durable revenue with limited competition.
- Broad geographic diversification reduces dependence on US drug pricing policy.
Key risks
- Large China exposure carries both political and pricing risk that peers do not have.
- US tariff and drug pricing policy has been a persistent overhang for non-US pharmaceutical companies.
- Several late-stage readouts are binary and the stock reacts violently to them; the August 2026 halt of the Phase 3 volrustomig lung cancer trial is a recent example.
Recent developments
- 2026-09-29 · AstraZeneca agreed a $2B preferred equity investment in Summit Therapeutics at $18.36/share (about 12% stake) plus an ivonescimab trial collaboration; completed 5 October. source
- 2026-09-01 · Tagrisso plus Orpathys met its PFS endpoint in Phase 3 SANOVO; EU approved Enhertu plus pertuzumab for first-line HER2-positive metastatic breast cancer. source
- 2026-08-18 · AstraZeneca discontinued Phase 3 eVOLVE-Lung02 of volrustomig plus chemotherapy in first-line metastatic NSCLC as unlikely to meet PFS or OS endpoints. source
Revenue by segment
| Oncology | 42% |
| BioPharmaceuticals (CVRM & R&I) | 45% |
| Rare Disease (Alexion) | 13% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $66.6B | $9.8B |
| Year 2 | $71.5B | $10.6B |
| Year 3 | $76.7B | $11.5B |
| Year 4 | $82.4B | $12.4B |
| Year 5 | $88.4B | $13.4B |
What the street says
Well regarded on pipeline depth, reinforced in September 2026 by the SANOVO lung cancer result and an EU approval for Enhertu with pertuzumab. The recurring debate is how to value the China business and whether US policy risk is adequately discounted.
Comparable companies: SYK · TMO · MRK · ABT · MDT · JNJ · GILD · SNY
Open the interactive model, price chart and sensitivity grid →